Genomics and drug profiling of fatal TCF3-HLFâ 'positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options

Nature Genetics

Volumn 47, Issue 9, 2015, Pages 1020-1029

  Fischer, Ute ^a   Forster, Michael ^b   Rinaldi, Anna ^c   Risch, Thomas ^d   Sungalee, Stéphanie ^e   Warnatz, Hans Jörg ^d   Bornhauser, Beat ^c   Gombert, Michael ^a   Kratsch, Christina ^f   Stütz, Adrian M ^e   Sultan, Marc ^d   Tchinda, Joelle ^c   Worth, Catherine L ^d   Amstislavskiy, Vyacheslav ^d   Badarinarayan, Nandini ^b   Baruchel, André ^g   Bartram, Thies ^b   Basso, Giuseppe ^h   Canpolat, Cengiz ⁱ   Cario, Gunnar ^b   Cavé, Hélène ^g   Dakaj, Dardane ^c   Delorenzi, Mauro ^j,k   Dobay, Maria Pamela ^k   Eckert, Cornelia ^l   Ellinghaus, Eva ^b   Eugster, Sabrina ^c   Frismantas, Viktoras ^c   Ginzel, Sebastian ^a,m   Haas, Oskar A ⁿ   Heidenreich, Olaf ^o   Hemmrich Stanisak, Georg ^b   Hezaveh, Kebria ^a   Höll, Jessica I ^a   Hornhardt, Sabine ^p   Husemann, Peter ^a   Kachroo, Priyadarshini ^b   Kratz, Christian P ^q   Kronnie, Geertruy Te ^h   Marovca, Blerim ^c   Niggli, Felix ^c   McHardy, Alice C ^f   Moorman, Anthony V ^o   Panzer Grümayer, Renate ⁿ   Petersen, Britt S ^b   Raeder, Benjamin ^e   Ralser, Meryem ^d   Rosenstiel, Philip ^b   Schäfer, Daniel ^a   Schrappe, Martin ^b   Schreiber, Stefan ^b   Schütte, Moritz ^r   Stade, Björn ^b   Thiele, Ralf ^m   Weid, Nicolas Von Der ^s   Vora, Ajay ^t   Zaliova, Marketa ^q,u   Zhang, Langhui ^a,v   Zichner, Thomas ^e   Zimmermann, Martin ^q   Lehrach, Hans ^d,r,w   Borkhardt, Arndt ^a   Bourquin, Jean Pierre ^c   Franke, Andre ^b   Korbel, Jan O ^e   Stanulla, Martin ^q   Yaspo, Marie Laure ^d   more..

^a Department of Orthopedic Surgery   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

^c UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^d MAX PLANCK INSTITUTE FOR MOLECULAR GENETICS   (Germany)

^e EUROPEAN MOLECULAR BIOLOGY LABORATORY   (Germany)

^f HEINRICH HEINE UNIVERSITY   (Germany)

^g HÔPITAL ROBERT DEBRÉ   (France)

^h UNIVERSITY OF PADOVA   (Italy)

ⁱ ACIBADEM UNIVERSITY   (Turkey)

^j UNIVERSITY OF LAUSANNE   (Switzerland)

^k SWISS INSTITUTE OF BIOINFORMATICS   (Switzerland)

^l CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^m Bonn Rhine Sieg University of Applied Sciences   (Germany)

ⁿ CHILDREN'S CANCER RESEARCH INSTITUTE   (Austria)

^o NEWCASTLE UNIVERSITY   (United Kingdom)

^p BUNDESAMT FÜR STRAHLENSCHUTZ   (Germany)

^q HANNOVER MEDICAL SCHOOL   (Germany)

^r ALACRIS THERANOSTICS GMBH   (Germany)

^s UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^t SHEFFIELD CHILDREN S HOSPITAL   (United Kingdom)

^u CHARLES UNIVERSITY   (Czech Republic)

^v FUJIAN MEDICAL UNIVERSITY   (China)

^w Dahlem Centre for Genome Research and Medical Systems Biology   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BORTEZOMIB; CD19 ANTIGEN; CD22 ANTIGEN; CD79B ANTIGEN; DASATINIB; DEXAMETHASONE; DNA; HLF PROTEIN; K RAS PROTEIN; LUMINESPIB; PREDNISONE; PROTEIN; PROTEIN BCL 2; PROTEIN KINASE LCK; PROTEIN TYROSINE PHOSPHATASE SHP 2; RAG1 PROTEIN; SPHINGOSINE KINASE 1; TRANSCRIPTION FACTOR 7 LIKE 1; TRANSCRIPTION FACTOR PAX5; TRANSCRIPTION FACTOR PBX1; TRANSCRIPTOME; UNCLASSIFIED DRUG; VENETOCLAX; VINCRISTINE; ANTINEOPLASTIC AGENT; ONCOPROTEIN; PAX5 PROTEIN, HUMAN; PRE-B-LYMPHOCYTE GENE 1 PROTEIN, HUMAN; SURROGATE IMMUNOGLOBULIN LIGHT CHAIN; TCF3-HLF FUSION PROTEIN, HUMAN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; CANCER GROWTH; CELL SURVIVAL; CHROMOSOME DELETION; COHORT ANALYSIS; CONSENSUS SEQUENCE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE DELETION; GENE DOSAGE; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; GENOMICS; HIGH THROUGHPUT SEQUENCING; HUMAN; HUMAN CELL; INDUCTION CHEMOTHERAPY; LEUKEMIA REMISSION; MALE; MOUSE; NONHUMAN; NONSENSE MUTATION; ONCOGENE K RAS; ONCOGENE N RAS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SOMATIC MUTATION; XENOGRAFT; ANIMAL; COCULTURE; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE; DRUG SCREENING; GENETIC ASSOCIATION STUDY; GENETICS; IC50; KAPLAN MEIER METHOD; METABOLISM; MORTALITY; MUTATION; NONOBESE DIABETIC MOUSE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SCID MOUSE;

ANIMALS; ANTINEOPLASTIC AGENTS; COCULTURE TECHNIQUES; COHORT STUDIES; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION STUDIES; GENOMICS; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS, SURROGATE; INHIBITORY CONCENTRATION 50; KAPLAN-MEIER ESTIMATE; MALE; MICE, INBRED NOD; MICE, SCID; MUTATION; ONCOGENE PROTEINS, FUSION; PAX5 TRANSCRIPTION FACTOR; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SEQUENCE DELETION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84940575993     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng.3362     Document Type: Article

References (85)

1. Mullighan, C.G. et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 446, 758-764 (2007).
2. Russell, L.J. et al. Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. Blood 114, 2688-2698 (2009).
3. Mullighan, C.G. et al. Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat. Genet. 41, 1243-1246 (2009).
4. Hertzberg, L. et al. Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group. Blood 115, 1006-1017 (2010).
5. Holmfeldt, L. et al. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat. Genet. 45, 242-252 (2013).
6. Zhang, J. et al. Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood 118, 3080-3087 (2011).
7. Irving, J. et al. Ras pathway mutations are highly prevalent in relapsed childhood acute lymphoblastic leukaemia, may act as relapse-drivers and confer sensitivity to MEK inhibition. Blood 124, 3420-3430 (2014).
8. Inaba, H., Greaves, M. & Mullighan, C.G. Acute lymphoblastic leukaemia. Lancet 381, 1943-1955 (2013).
9. Kwon, K. et al. Instructive role of the transcription factor E2A in early B lymphopoiesis and germinal center B cell development. Immunity 28, 751-762 (2008).
10. Felice, M.S. et al. Prognostic impact of t(1;19)/ TCF3-PBX1 in childhood acute lymphoblastic leukemia in the context of Berlin-Frankfurt-Munster-based protocols. Leuk. Lymphoma 52, 1215-1221 (2011).
11. Hunger, S.P., Ohyashiki, K., Toyama, K. & Cleary, M.L. Hlf, a novel hepatic bZIP protein, shows altered DNA-binding properties following fusion to E2A in t(17;19) acute lymphoblastic leukemia. Genes Dev. 6, 1608-1620 (1992).
12. Inukai, T. et al. Hypercalcemia in childhood acute lymphoblastic leukemia: frequent implication of parathyroid hormone-related peptide and E2A-HLF from translocation 17;19. Leukemia 21, 288-296 (2007).
13. Boller, S. & Grosschedl, R. The regulatory network of B-cell differentiation: a focused view of early B-cell factor 1 function. Immunol. Rev. 261, 102-115 (2014).
14. de Boer, J. et al. The E2A-HLF oncogenic fusion protein acts through Lmo2 and Bcl-2 to immortalize hematopoietic progenitors. Leukemia 25, 321-330 (2011).
15. Hirose, K. et al. Aberrant induction of LMO2 by the E2A-HLF chimeric transcription factor and its implication in leukemogenesis of B-precursor ALL with t(17;19). Blood 116, 962-970 (2010).
16. Inukai, T. et al. SLUG, a ces-1-related zinc fnger transcription factor gene with antiapoptotic activity, is a downstream target of the E2A-HLF oncoprotein. Mol. Cell 4, 343-352 (1999).
17. Inoue, A. et al. Slug, a highly conserved zinc fnger transcriptional repressor, protects hematopoietic progenitor cells from radiation-induced apoptosis in vivo. Cancer Cell 2, 279-288 (2002).
18. Honda, H. et al. Expression of E2A-HLF chimeric protein induced T-cell apoptosis, B-cell maturation arrest, and development of acute lymphoblastic leukemia. Blood 93, 2780-2790 (1999).
19. Smith, K.S., Rhee, J.W., Naumovski, L. & Cleary, M.L. Disrupted differentiation and oncogenic transformation of lymphoid progenitors in E2A-HLF transgenic mice. Mol. Cell. Biol. 19, 4443-4451 (1999).
20. Hunger, S.P. Chromosomal translocations involving the E2A gene in acute lymphoblastic leukemia: clinical features and molecular pathogenesis. Blood 87, 1211-1224 (1996).
21. Wiemels, J.L. et al. Site-specifc translocation and evidence of postnatal origin of the t(1;19) E2A-PBX1 fusion in childhood acute lymphoblastic leukemia. Proc. Natl. Acad. Sci. USA 99, 15101-15106 (2002).
22. Tsai, A.G. et al. Human chromosomal translocations at CpG sites and a theoretical basis for their lineage and stage specifcity. Cell 135, 1130-1142 (2008).
23. Moorman, A.V. et al. A novel integrated cytogenetic and genomic classifcation refnes risk stratifcation in pediatric acute lymphoblastic leukemia. Blood 124, 1434-1444 (2014).
24. Mangum, D.S. et al. VPREB1 deletions occur independent of lambda light chain rearrangement in childhood acute lymphoblastic leukemia. Leukemia 28, 216-220 (2014).
25. Waanders, E. et al. The origin and nature of tightly clustered BTG1 deletions in precursor B-cell acute lymphoblastic leukemia support a model of multiclonal evolution. PLoS Genet. 8, e1002533 (2012).
26. Tijchon, E., Havinga, J., van Leeuwen, F.N. & Scheijen, B. B-lineage transcription factors and cooperating gene lesions required for leukemia development. Leukemia 27, 541-552 (2013).
27. Balbin, O.A. et al. Reconstructing targetable pathways in lung cancer by integrating diverse omics data. Nat. Commun. 4, 2617 (2013).
28. Wright, D.D., Sefton, B.M. & Kamps, M.P. Oncogenic activation of the Lck protein accompanies translocation of the LCK gene in the human HSB2 T-cell leukemia. Mol. Cell. Biol. 14, 2429-2437 (1994).
29. Schmitz, R. et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature 490, 116-120 (2012).
30. Ma, X. et al. Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia. Nat. Commun. 6, 6604 (2015).
31. Laurenti, E. et al. The transcriptional architecture of early human hematopoiesis identifes multilevel control of lymphoid commitment. Nat. Immunol. 14, 756-763 (2013).
32. Subramanian, A., Kuehn, H., Gould, J., Tamayo, P. & Mesirov, J.P. GSEA-P: a desktop application for Gene Set Enrichment Analysis. Bioinformatics 23, 3251-3253 (2007).
33. + stem cell activity in mouse intestinal adenomas. Science 337, 730-735 (2012).
34. Akahane, K. et al. Specifc induction of CD33 expression by E2A-HLF: the frst evidence for aberrant myeloid antigen expression in ALL by a fusion transcription factor. Leukemia 24, 865-869 (2010).
35. Nissim, S. et al. Prostaglandin E2 regulates liver versus pancreas cell-fate decisions and endodermal outgrowth. Dev. Cell 28, 423-437 (2014).
36. Schmitz, M. et al. Xenografts of highly resistant leukemia recapitulate the clonal composition of the leukemogenic compartment. Blood 118, 1854-1864 (2011).
37. Bonapace, L. et al. Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance. J. Clin. Invest. 120, 1310-1323 (2010).
38. Stark, Z. et al. Two novel germline KRAS mutations: expanding the molecular and clinical phenotype. Clin. Genet. 81, 590-594 (2012).
39. Boutter, J. et al. Image-based RNA interference screening reveals an individual dependence of acute lymphoblastic leukemia on stromal cysteine support. Oncotarget 5, 11501-11512 (2014).
40. Bicocca, V.T. et al. Crosstalk between ROR1 and the Pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia. Cancer Cell 22, 656-667 (2012).
41. Heltemes-Harris, L.M. et al. Ebf1 or Pax5 haploinsuffciency synergizes with STAT5 activation to initiate acute lymphoblastic leukemia. J. Exp. Med. 208, 1135-1149 (2011).
42. Souers, A.J. et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat. Med. 19, 202-208 (2013).
43. Rolink, A.G., Nutt, S.L., Melchers, F. & Busslinger, M. Long-term in vivo reconstitution of T-cell development by Pax5-defcient B-cell progenitors. Nature 401, 603-606 (1999).
44. Joshi, I. et al. Loss of Ikaros DNA-binding function confers integrin-dependent survival on pre-B cells and progression to acute lymphoblastic leukemia. Nat. Immunol. 15, 294-304 (2014).
45. Clappier, E. et al. An intragenic ERG deletion is a marker of an oncogenic subtype of B-cell precursor acute lymphoblastic leukemia with a favorable outcome despite frequent IKZF1 deletions. Leukemia 28, 70-77 (2014).
46. Grawunder, U. et al. Down-regulation of RAG1 and RAG2 gene expression in preB cells after functional immunoglobulin heavy chain rearrangement. Immunity 3, 601-608 (1995).
47. Den Boer, M.L. et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classifcation study. Lancet Oncol. 10, 125-134 (2009).
48. Andersson, A.K. et al. The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias. Nat. Genet. 47, 330-337 (2015).
49. Barker, N. et al. Identifcation of stem cells in small intestine and colon by marker gene Lgr5. Nature 449, 1003-1007 (2007).
50. Liu, D. et al. Leucine-rich repeat-containing G-protein-coupled Receptor 5 marks short-term hematopoietic stem and progenitor cells during mouse embryonic development. J. Biol. Chem. 289, 23809-23816 (2014).
51. Riddell, J. et al. Reprogramming committed murine blood cells to induced hematopoietic stem cells with defned factors. Cell 157, 549-564 (2014).
52. Sandler, V.M. et al. Reprogramming human endothelial cells to haematopoietic cells requires vascular induction. Nature 511, 312-318 (2014).
53. Urbánek, P. , Wang, Z.Q., Fetka, I., Wagner, E.F. & Busslinger, M. Complete block of early B cell differentiation and altered patterning of the posterior midbrain in mice lacking Pax5/BSAP. Cell 79, 901-912 (1994).
54. Simmons, S. et al. Biphenotypic B-lymphoid/myeloid cells expressing low levels of Pax5: potential targets of BAL development. Blood 120, 3688-3698 (2012).
55. Papaemmanuil, E. et al. RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia. Nat. Genet. 46, 116-125 (2014).
56. Peirs, S. et al. ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia. Blood 124, 3738-3747 (2014).
57. Chonghaile, T.N. et al. Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199. Cancer Discov. 4, 1074-1087 (2014).
58. El Omari, K. et al. Structural basis for LMO2-driven recruitment of the SCL: E47bHLH heterodimer to hematopoietic-specifc transcriptional targets. Cell Rep. 4, 135-147 (2013).
59. Conter, V. et al. Molecular response to treatment redefnes all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 115, 3206-3214 (2010).
60. Harrison, C.J. et al. Detection of prognostically relevant genetic abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: recommendations from the Biology and Diagnosis Committee of the International Berlin-Frankfurt-Munster study group. Br. J. Haematol. 151, 132-142 (2010).
61. Case, M. et al. Mutation of genes affecting the RAS pathway is common in childhood acute lymphoblastic leukemia. Cancer Res. 68, 6803-6809 (2008).
62. Dörge, P. et al. IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol. Haematologica 98, 428-432 (2013).
63. Bauer, M.J., Cox, A.J. & Evers, D.J. Fast gapped read mapping for Illumina reads. In ISMB, ISBC (2010).
64. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754-1760 (2009).
65. Rausch, T. et al. DELLY: structural variant discovery by integrated paired-end and split-read analysis. Bioinformatics 28, i333-i339 (2012).
66. Xi, R. et al. Copy number variation detection in whole-genome sequencing data using the Bayesian information criterion. Proc. Natl. Acad. Sci. USA 108, E1128-E1136 (2011).
67. Kim, D. et al. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol. 14, R36 (2013).
68. McPherson, A. et al. deFuse: an algorithm for gene fusion discovery in tumor RNA-Seq data. PLOS Comput. Biol. 7, e1001138 (2011).
69. McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297-1303 (2010).
70. Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31, 213-219 (2013).
71. Forster, M. et al. From next-generation sequencing alignments to accurate comparison and validation of single-nucleotide variants: the pibase software. Nucleic Acids Res. 41, e16 (2013).
72. Li, H. et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 2078-2079 (2009).
73. Koboldt, D.C. et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 22, 568-576 (2012).
74. Albers, C.A. et al. Dindel: accurate indel calls from short-read data. Genome Res. 21, 961-973 (2011).
75. Mortazavi, A., Williams, B.A., McCue, K., Schaeffer, L. & Wold, B. Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat. Methods 5, 621-628 (2008).
76. Robinson, M.D., McCarthy, D.J. & Smyth, G.K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139-140 (2010).
77. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profles. Proc. Natl. Acad. Sci. USA 102, 15545-15550 (2005).
78. Frisch, M., Klocke, B., Haltmeier, M. & Frech, K. LitInspector: literature and signal transduction pathway mining in PubMed abstracts. Nucleic Acids Res. 37, W135-W140 (2009).
79. Ho Sui, S.J. et al. oPOSSUM: identifcation of over-represented transcription factor binding sites in co-expressed genes. Nucleic Acids Res. 33, 3154-3164 (2005).
80. Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 38, e164 (2010).
81. 1000 Genomes Project Consortium. A map of human genome variation from population-scale sequencing. Nature 467, 1061-1073 (2010).
82. Stade, B., Seelow, D., Thomsen, I., Krawczak, M. & Franke, A. GrabBlur-A framework to facilitate the secure exchange of whole-exome and -genome SNV data using VCF fles. BMC Genomics 15 (suppl. 4), S8 (2014).
83. Robinson, J.T. et al. Integrative genomics viewer. Nat. Biotechnol. 29, 24-26 (2011).
84. Ratei, R. et al. Lineage classifcation of childhood acute lymphoblastic leukemia according to the EGIL recommendations: results of the ALL-BFM 2000 trial. Klin. Padiatr. 225 (suppl. 1), S34-S39 (2013).
85. Festing, M.F. & Altman, D.G. Guidelines for the design and statistical analysis of experiments using laboratory animals. ILAR J. 43, 244-258 (2002).